MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Cancer Network' source. Sat, 20 Mar 2010 13:49:59 +0100 http://www.medworm.com/index.php?rid=3380071&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2Fmelanoma-skin-cancer%2Fcontent%2Farticle%2F10165%2F1540801%3FCID%3Drss Study pinpoints factors that put post-transplant patients at risk for non-melanoma skin cancers. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3380071 Fri, 19 Mar 2010 13:30:02 +0100 3380071 http://www.medworm.com/index.php?rid=3375488&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2Fgastrointestinal-cancer%2Fcontent%2Farticle%2F10165%2F1539972%3FCID%3Drss Pretreated patients with metastatic gastric cancer experienced a boost in overall survival after treatment with everolimus (Afinitor), according to the results of a phase II trial presented at the 2010 Gastrointestinal Cancers Symposium. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3375488 Thu, 18 Mar 2010 13:30:02 +0100 3375488 http://www.medworm.com/index.php?rid=3380078&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2Flung-cancer%2Fcontent%2Farticle%2F10165%2F1540509%3FCID%3Drss Testing for EGFR and ALK mutations reveals tumor behavior and helps tailor treatment. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3380078 Thu, 18 Mar 2010 12:00:00 +0100 3380078 http://www.medworm.com/index.php?rid=3380077&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2Fcancer-genetics%2Fcontent%2Farticle%2F10165%2F1540534%3FCID%3Drss A collaborative project to sequence the neuroblastoma cancer genome could revolutionize diagnosis and treatment. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3380077 Thu, 18 Mar 2010 12:00:00 +0100 3380077 http://www.medworm.com/index.php?rid=3380076&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2Fleukemia-lymphoma%2Fcontent%2Farticle%2F10165%2F1540579%3FCID%3Drss In asymptomatic disease, overall survival is often the same with immediate treatment vs watch and wait. The deciding factor may be what patients are willing to tolerate. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3380076 Thu, 18 Mar 2010 12:00:00 +0100 3380076 http://www.medworm.com/index.php?rid=3380075&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2Fpancreatic-cancer%2Fcontent%2Farticle%2F10165%2F1540616%3FCID%3Drss A novel IGF-receptor inhibitor stabilized disease in a majority of pancreatic cancer patients, according to a report at the 2010 GI Cancers Symposium. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3380075 Thu, 18 Mar 2010 12:00:00 +0100 3380075 http://www.medworm.com/index.php?rid=3380074&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2Fleukemia-lymphoma%2Fcontent%2Farticle%2F10165%2F1540652%3FCID%3Drss Unlike conventional radiation, Yttrium-90-ibritumomab tiuxetan (Zevalin) induces cellular damage only in the targeted tumor cells and has demonstrated activity in follicular and diffuse large B-cell non-Hodgkin’s lymphoma. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3380074 Thu, 18 Mar 2010 12:00:00 +0100 3380074 http://www.medworm.com/index.php?rid=3380073&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2Fbreast-cancer%2Fcontent%2Farticle%2F10165%2F1540726%3FCID%3Drss Study in Asian population runs counter to previous concern that phytoestrogen in soy may increase disease risk. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3380073 Thu, 18 Mar 2010 12:00:00 +0100 3380073 http://www.medworm.com/index.php?rid=3380072&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2Fcolorectal-cancer%2Fcontent%2Farticle%2F10165%2F1540772%3FCID%3Drss Four years ago, at least five years of statin use was found to be associated with a 53% reduction in the risk of colorectal cancer and that association still stands, according to a coauthor of one of the initial studies to make the statin-cancer connection. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3380072 Thu, 18 Mar 2010 12:00:00 +0100 3380072 http://www.medworm.com/index.php?rid=3371355&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1538613%3FCID%3Drss Removing an oropharyngeal tumor through the open mouth using robotic instruments now has FDA approval, and its safety is well documented. Comparative evidence of its effectiveness is beginning to trickle in. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3371355 Wed, 17 Mar 2010 13:30:01 +0100 3371355 http://www.medworm.com/index.php?rid=3375491&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2Fcolorectal-cancer%2Fcontent%2Farticle%2F10165%2F1539620%3FCID%3Drss A primer on managing the chemorefractory patient from Eric Van Cutsem, MD, PhD. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3375491 Wed, 17 Mar 2010 12:00:00 +0100 3375491 http://www.medworm.com/index.php?rid=3375490&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1539730%3FCID%3Drss For quality to become the standard, care delivery must be fundamentally changed and oncologists will need to step up to work with insurance providers. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3375490 Wed, 17 Mar 2010 12:00:00 +0100 3375490 http://www.medworm.com/index.php?rid=3375489&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2Fpancreatic-cancer%2Fcontent%2Farticle%2F10165%2F1539927%3FCID%3Drss Screening is the key to protecting those at risk for pancreatic cancer, according to presenters at the 2010 Gastrointestinal Cancers Symposium. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3375489 Wed, 17 Mar 2010 12:00:00 +0100 3375489 http://www.medworm.com/index.php?rid=3367030&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2F264%2Farticle%2F10165%2F1537933%3FCID%3Drss A $450,000 grant from the Damon Runyon Cancer Research Foundation has been awarded to Heather Christofk, PhD. Read more about the latest awards and appointments. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3367030 Tue, 16 Mar 2010 13:30:02 +0100 3367030 http://www.medworm.com/index.php?rid=3351534&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1535741%3FCID%3Drss Hematologists/oncologists and other physicians can expect to encounter an increasing number of patients with multiple myeloma in the coming years. Between 1997 and 2006, the incidence rate of myeloma declined in the United States, but the burden (the number of incident cases) increased.[1] (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3351534 Thu, 11 Mar 2010 13:30:01 +0100 3351534 http://www.medworm.com/index.php?rid=3347765&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1535111%3FCID%3Drss are extremely rare neoplasms, which precludes determination of their true incidence. In 2009, approximately 2,570 new cases of cancer of the bones and joints will be diagnosed in the United States, and some 1,470 patients will succumb to the disease. Population-based tumor registries seldom separate bone sarcomas into various histologic types. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3347765 Wed, 10 Mar 2010 14:00:01 +0100 3347765 http://www.medworm.com/index.php?rid=3343544&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1534429%3FCID%3Drss No survival advantage of autologous stem cell transplantation (ASCT) has been documented for patients older than 65 years, and in the era of thalidomide (Thalomid), bortezomib (Velcade), and len­alidomide (Revlimid), ASCT has a diminished role in the front-line treatment of older patients with myeloma. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3343544 Tue, 09 Mar 2010 13:30:02 +0100 3343544 http://www.medworm.com/index.php?rid=3343548&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1534350%3FCID%3Drss Next-generation genomic assay technologies are revolutionizing our ability to characterize cancers at the genomic levels, providing critical prognostic and predictive information for individual patients with breast cancer, thereby helping to guide treatment decisions. According to Harold J. Burstein, MD, PhD, Associate Professor of Medicine, Harvard Medical School, these emerging technologies will change the way we treat breast cancer. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3343548 Mon, 08 Mar 2010 12:00:00 +0100 3343548 http://www.medworm.com/index.php?rid=3343547&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1534355%3FCID%3Drss High-dose melphalan (Alkeran) and autologous stem cell transplantation are commonly incorporated into the initial line of therapy for patients newly diagnosed with multiple myeloma. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3343547 Mon, 08 Mar 2010 12:00:00 +0100 3343547 http://www.medworm.com/index.php?rid=3343546&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1534368%3FCID%3Drss Internationally renowned breast cancer scientist, V. Craig Jordan, OBE, PhD, DSc posed an important question: Where do we go from here in endocrine therapy. In an interview with ONCOLOGY, Dr. Jordan highlighted some of the fundamental clinical issues that he explored during his presentation, “Challenges to Improve Adjuvant Endocrine Therapy.” (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3343546 Mon, 08 Mar 2010 12:00:00 +0100 3343546 http://www.medworm.com/index.php?rid=3343545&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1534376%3FCID%3Drss For oncologists battling breast cancer in the clinic, one of the most difficult decisions is choosing the optimal adjuvant therapy, one that balances the fine line between efficacy and toxicity. Clifford A. Hudis, MD, Chief, Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center, tackled this difficult clinical discussion in an interview with ONCOLOGY. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3343545 Mon, 08 Mar 2010 12:00:00 +0100 3343545 http://www.medworm.com/index.php?rid=3328341&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1531953%3FCID%3Drss News that President Obama received a clean bill of health from a virtual colonoscopy several days ago rubbed influential gastroenterologists the wrong way. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3328341 Thu, 04 Mar 2010 13:30:01 +0100 3328341 http://www.medworm.com/index.php?rid=3323789&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1531047%3FCID%3Drss On Feb. 28 President Obama was screened for colorectal cancer using CT colonography. The results from this exam, also called virtual colonoscopy, along with those from the rest of the president’s annual physical, which was done at the National Naval Medical Center in Bethesda, described the president as “fit for duty.” (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3323789 Wed, 03 Mar 2010 13:30:01 +0100 3323789 http://www.medworm.com/index.php?rid=3319222&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1530443%3FCID%3Drss It’s a kind of man bites dog story: unusual, remarkable, yet oddly plausible. The Centers for Medicare and Medicaid Services has told its contractors to hold claims containing services paid under the Medicare Physician Fee Schedule for the first 10 business days of March. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3319222 Tue, 02 Mar 2010 13:30:01 +0100 3319222 http://www.medworm.com/index.php?rid=3308163&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1527699%3FCID%3Drss African Americans have a higher mortality rate from lung cancer than whites, a fact first discovered in the early 1980s. For decades, researchers have looked for differences in access to care, rates of surgery, and patient preferences to explain the disparity. Now it seems the answer may relate at least partly to the way African Americans think about lung cancer, according to a survey conducted by the Dana-Farber Cancer Institute. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3308163 Fri, 26 Feb 2010 13:30:01 +0100 3308163 http://www.medworm.com/index.php?rid=3343550&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1529971%3FCID%3Drss Ron Piana, Executive Editor for Special Projects with the journal ONCOLOGY, spoke with nationally regarded breast cancer specialist, Dr. Debu Tripathy, co-course director for the 27th Annual Miami Breast Cancer Conference. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3343550 Fri, 26 Feb 2010 12:00:00 +0100 3343550 http://www.medworm.com/index.php?rid=3343549&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1529980%3FCID%3Drss Nationally recognized breast cancer specialist Eric P. Winer, MD, presented two lectures at this year’s MBCC, “Strategies for Patients with Refractory HER2-Positive Breast Cancer,” and “Addressing Menopausal Symptoms and Fertility in Breast Cancer.” In an exclusive interview with ONCOLOGY, Dr. Winer explained how hormonal therapy can best be used in the difficult stetting of metastatic disease. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3343549 Fri, 26 Feb 2010 12:00:00 +0100 3343549 http://www.medworm.com/index.php?rid=3319224&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1529971%3FCID%3Drss Ron Piana, Executive Editor for Special Projects with the journal ONCOLOGY, spoke with nationally regarded breast cancer specialist, Dr. Debu Tripathy, co-course director for the 27th Annual Miami Breast Cancer Conference. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3319224 Fri, 26 Feb 2010 12:00:00 +0100 3319224 http://www.medworm.com/index.php?rid=3319223&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1529980%3FCID%3Drss Reporting from the MBCC, ONCOLOGY spoke with Eric P. Winer, MD, Director, Breast Oncology Center; Chief, Division of Women's Cancers; Thompson Senior Investigator in Breast Cancer Research, Dana-Farber Cancer Institute. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3319223 Fri, 26 Feb 2010 12:00:00 +0100 3319223 http://www.medworm.com/index.php?rid=3299560&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1527699%3FCID%3Drss African Americans have a higher mortality rate from lung cancer than whites, a fact first discovered in the early 1980s. For decades, researchers have looked for differences in access to care, rates of surgery, and patient preferences to explain the disparity. Now it seems the answer may relate at least partly to the way African Americans think about lung cancer, according to a survey conducted by the Dana-Farber Cancer Institute. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3299560 Wed, 24 Feb 2010 13:30:01 +0100 3299560 http://www.medworm.com/index.php?rid=3295594&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1526853%3FCID%3Drss Induction therapy with higher daily doses of daunorubicin improved complete response and boosted overall survival in younger patients with acute myelogenous leukemia, according to results of the phase III ECOG E1900 trial. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295594 Tue, 23 Feb 2010 13:30:01 +0100 3295594 http://www.medworm.com/index.php?rid=3295604&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1526595%3FCID%3Drss The seminal IPASS study by Tony Mok, MD, and colleagues demonstrated moderate efficacy for gefitinib (Iressa) in advanced non–small–cell lung cancer patients, most notably in patients with predictive factors, including adenocarcinoma histology, no history of smoking, and Asian ethnicity. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295604 Mon, 22 Feb 2010 12:00:00 +0100 3295604 http://www.medworm.com/index.php?rid=3295603&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1526601%3FCID%3Drss The FDA granted accelerated approval for the use of lapatinib (Tykerb) with letrozole (Femara) as a first-line, oral treatment for women with metastatic disease. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295603 Mon, 22 Feb 2010 12:00:00 +0100 3295603 http://www.medworm.com/index.php?rid=3295602&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1526623%3FCID%3Drss Using renal mass biopsy to guide treatment decisions for small tumors is cost-effective relative to direct surgery, and can spare many patients unnecessary surgical procedures, according to Massachusetts General Hospital researchers. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295602 Mon, 22 Feb 2010 12:00:00 +0100 3295602 http://www.medworm.com/index.php?rid=3295601&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1526637%3FCID%3Drss A second round of gefitinib (Iressa) slowed disease advancement in non-small-cell lung cancer patients who failed to respond to first-line treatment, according to a study presented at the 2010 Joint Conference on Molecular Origins in Lung Cancer. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295601 Mon, 22 Feb 2010 12:00:00 +0100 3295601 http://www.medworm.com/index.php?rid=3295600&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1526642%3FCID%3Drss Also, French surgical oncologists discuss their experience with treament of heterogenous Merkel cell carcinoma. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295600 Mon, 22 Feb 2010 12:00:00 +0100 3295600 http://www.medworm.com/index.php?rid=3295599&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1526659%3FCID%3Drss Higher doses of the estrogen-receptor antagonist fulvestrant (Faslodex) may increase treatment benefit without increasing toxicity, according to results from the international, randomized, double-blind phase III CONFIRM trial. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295599 Mon, 22 Feb 2010 12:00:00 +0100 3295599 http://www.medworm.com/index.php?rid=3295598&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1526692%3FCID%3Drss Fulvestrant-anastrozole combination did not demonstrate advantage despite a better dose loading schedule and compelling preclinical data. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295598 Mon, 22 Feb 2010 12:00:00 +0100 3295598 http://www.medworm.com/index.php?rid=3295597&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1526707%3FCID%3Drss The U.S. Radiation Therapy Oncology Group has greenlighted the routine use of SBRT, but physicians overseas call for more scientific evidence to support its widespread use. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295597 Mon, 22 Feb 2010 12:00:00 +0100 3295597 http://www.medworm.com/index.php?rid=3295596&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1526812%3FCID%3Drss Modeling study calculates that the adoption of proton therapy is possible if it is based on clinical evidence and not market forces. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295596 Mon, 22 Feb 2010 12:00:00 +0100 3295596 http://www.medworm.com/index.php?rid=3295595&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1526837%3FCID%3Drss The RIBBON-2 trial met its primary endpoint of prolonged progression-free survival. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295595 Mon, 22 Feb 2010 12:00:00 +0100 3295595 http://www.medworm.com/index.php?rid=3285145&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2F264%2Farticle%2F10165%2F1525822%3FCID%3Drss The RANK ligand inhibitor was better tolerated and more convenient for patients with skeletal metastasis. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285145 Fri, 19 Feb 2010 13:30:01 +0100 3285145 http://www.medworm.com/index.php?rid=3280995&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1524851%3FCID%3Drss Concerned that erythropoiesis-stimulating agents may actually undo what chemotherapy has done, promoting tumor progression or recurrence and shortening overall survival, the FDA is clamping down on these products, marketed by Amgen as Aranesp (darbepoetin alfa) and Epogen (epoetin alfa), and by Centocor Ortho Biotech Products as Procrit (epoetin alfa). (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3280995 Thu, 18 Feb 2010 13:30:01 +0100 3280995 http://www.medworm.com/index.php?rid=3295607&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1525698%3FCID%3Drss The imaging technique has the potential to measure the extent and depth of skin lesions. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295607 Thu, 18 Feb 2010 12:00:00 +0100 3295607 http://www.medworm.com/index.php?rid=3295606&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1525763%3FCID%3Drss Experts from health systems, government, and the insurance industry offer insights into how quality is defined and measured in medicine today. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295606 Thu, 18 Feb 2010 12:00:00 +0100 3295606 http://www.medworm.com/index.php?rid=3295605&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1525822%3FCID%3Drss The RANK ligand inhibitor was better tolerated and more convenient for patients with skeletal metastasis. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3295605 Thu, 18 Feb 2010 12:00:00 +0100 3295605 http://www.medworm.com/index.php?rid=3285148&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1525501%3FCID%3Drss Less than 1% of women took tamoxifen in the years 2000 and 2005 as a preventive measure, according to results of a recent survey. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285148 Thu, 18 Feb 2010 12:00:00 +0100 3285148 http://www.medworm.com/index.php?rid=3285147&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2F264%2Farticle%2F10165%2F1525698%3FCID%3Drss The imaging technique has the potential to measure the extent and depth of skin lesions. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285147 Thu, 18 Feb 2010 12:00:00 +0100 3285147 http://www.medworm.com/index.php?rid=3285146&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fweb%2F10165%2F264%2Farticle%2F10165%2F1525763%3FCID%3Drss Experts from health systems, government, and the insurance industry offer insights into how quality is defined and measured in medicine today. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285146 Thu, 18 Feb 2010 12:00:00 +0100 3285146 http://www.medworm.com/index.php?rid=3285149&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1524522%3FCID%3Drss None; investigational agents olaparib (AZD2281) and BSI-201 are in phase I and II clinical trials; other PARP inhibitors under investigation include AGO 14699 (Pfizer), ABT-888 (Enzo), and MK4827 (Merck). (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285149 Wed, 17 Feb 2010 12:00:00 +0100 3285149 http://www.medworm.com/index.php?rid=3285157&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1523329%3FCID%3Drss As a new decade unfolds, we are very fortunate to have an increasing number of new interventions available because of the recent tremendous advances in genetics and genomics. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285157 Tue, 16 Feb 2010 12:00:00 +0100 3285157 http://www.medworm.com/index.php?rid=3285156&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1523346%3FCID%3Drss Genetic and genomic research is creating new and more individualized approaches to better manage a person's disease or predisposition to disease, including cancer. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285156 Tue, 16 Feb 2010 12:00:00 +0100 3285156 http://www.medworm.com/index.php?rid=3285155&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1523357%3FCID%3Drss Lea and Calzone have provided an outstanding overview of genetics and genomic research applicable to the subspecialty of oncology nursing. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285155 Tue, 16 Feb 2010 12:00:00 +0100 3285155 http://www.medworm.com/index.php?rid=3285154&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1523362%3FCID%3Drss At least half of all Americans are at risk for consequences resulting from low health literacy (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285154 Tue, 16 Feb 2010 12:00:00 +0100 3285154 http://www.medworm.com/index.php?rid=3285153&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1523565%3FCID%3Drss Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most challenging and complex complications of cancer chemotherapy. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285153 Tue, 16 Feb 2010 12:00:00 +0100 3285153 http://www.medworm.com/index.php?rid=3285152&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1523570%3FCID%3Drss Owing to the success of today’s cancer treatments, many cancer survivors are now living through and beyond the cancer experience. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285152 Tue, 16 Feb 2010 12:00:00 +0100 3285152 http://www.medworm.com/index.php?rid=3285151&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1523580%3FCID%3Drss , the rhizome of Zingiber officinale Roscoe, is best known for its role as a flavoring agent for food in Asian and Indian recipes. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285151 Tue, 16 Feb 2010 12:00:00 +0100 3285151 http://www.medworm.com/index.php?rid=3285150&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1523633%3FCID%3Drss Cognitive impairment, including memory loss, inability to concentrate, and difficulty multitasking, has become a widely recognized possible late effect of chemotherapy and cancer treatment. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285150 Tue, 16 Feb 2010 12:00:00 +0100 3285150 http://www.medworm.com/index.php?rid=3263936&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1522646%3FCID%3Drss Cancer researchers at Children’s Hospital Boston have reported a protein previously unknown to be involved in taxane resistance and could potentially be targeted with drugs, making a cancer more susceptible to chemotherapy. The researchers believe that this protein, prohibitin1, could also serve as a biomarker, allowing doctors to predict a patient’s response to chemotherapy with a simple blood test. The study was published online by the Proceedings of the National Academy of Sciences in its online early edition during the week of January 25. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3263936 Fri, 12 Feb 2010 13:30:02 +0100 3263936 http://www.medworm.com/index.php?rid=3285158&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1522202%3FCID%3Drss ASCO and RSNA elect new presidents while the Children's Oncology Group selects a new leader. Read more about the latest awards and appointments in oncology and cancer care. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3285158 Thu, 11 Feb 2010 12:00:00 +0100 3285158 http://www.medworm.com/index.php?rid=3263941&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1522330%3FCID%3Drss In this review, Ujjani and Cheson present a useful overview of the array of existing and developing roles for monoclonal antibodies in the management of B-cell non-Hodgkin lymphomas (NHLs). These roles may be characterized as single-agent antibody therapy, use in combination with chemotherapy and/or other antibodies, and use following an initial regimen (consolidation/maintenance). Rituximab (Rituxan), the first monoclonal antibody approved for B-cell NHL, clearly has had greatest application in each of these arenas, but it has now been joined by alemtuzumab (Campath) and ofatumumab (Arzerra) as approved single-agent therapies. Also highlighted are a number of other antibodies aimed at B-cell targets: veltuzumab, GA101, AME-133 (CD20), epratuzumab (CD22), lumiliximab (CD23), galiximab (CD8... Cancer Network info http://www.medworm.com/rss/comments.php?id=3263941 Thu, 11 Feb 2010 12:00:00 +0100 3263941 http://www.medworm.com/index.php?rid=3263940&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1522567%3FCID%3Drss Neoadjuvant therapy may provide advantages to some women with primary operable breast cancer. Compared to the administration of the same regimen in the adjuvant setting, neoadjuvant chemotherapy does not improve survival outcomes, but may provide other benefits. Neoadjuvant therapy is associated with improved rates of breast-conserving therapy, may offer prognostic information, and enables assessment of in vivo response to therapy. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3263940 Thu, 11 Feb 2010 12:00:00 +0100 3263940 http://www.medworm.com/index.php?rid=3263939&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1522608%3FCID%3Drss Large clinical trials have demonstrated that preoperative therapy for primary operable breast cancer improves breast-conservation rates, with equivalent disease-free (DFS) and overall survival (OS) compared to adjuvant therapy.[1] Connolly and Stearns provide an excellent review of additional benefits of neoadjuvant therapy and emphasize the importance of a multidisciplinary approach to treating patients in this setting. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3263939 Thu, 11 Feb 2010 12:00:00 +0100 3263939 http://www.medworm.com/index.php?rid=3263938&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1522631%3FCID%3Drss In my practice as an oncologist specializing in gastrointestinal tract cancers, a recent week was fairly typical. I saw 50 patients, ranging in age from 32 to 87, equally divided between men and women. Though a couple of them have inherited a gene that may have caused their GI cancers, I have no explanation for why most developed their disease. It is as if they were simply struck by lightning. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3263938 Thu, 11 Feb 2010 12:00:00 +0100 3263938 http://www.medworm.com/index.php?rid=3263937&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1522305%3FCID%3Drss No branch of oncology has been more attuned to the vision of new genetically engineered targeted therapies than the field of hematopoietic malignancies. Ujjani and Cheson have produced a masterful summary of one extremely important component of the targeted therapy revolution—the realm of monoclonal antibodies directed against malignant lymphoma surface antigens.[1] The review presents a wonderful update and a glimpse of future potentially curative macromolecular cocktails. It is an attractive vision. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3263937 Thu, 11 Feb 2010 12:00:00 +0100 3263937 http://www.medworm.com/index.php?rid=3256004&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1521034%3FCID%3Drss Shabason and colleagues’ review of the development of histone deacetylase (HDAC) inhibitors as treatment for cancers is timely, with an emphasis on therapeutic strategies combining HDAC inhibitors and radiation therapy. As the authors indicate, vorinostat (Zolinza)—originally known as suberoylanilide hydroxamic acid, or SAHA—was the first of the HDAC inhibitors approved by the US Food and Drug Administration (FDA) for clinical use in the treatment of cutaneous T-cell lymphoma (CTCL).[1] In November 2009, a second HDAC inhibitor—romidepsin (Istodax)—received FDA approval for the treatment of CTCL. Currently there is a great deal of competition in the HDAC inhibitor field, as several new and, hopefully, more effective compounds are being developed and entering clinical trials.[2] (... Cancer Network info http://www.medworm.com/rss/comments.php?id=3256004 Wed, 10 Feb 2010 13:30:01 +0100 3256004 http://www.medworm.com/index.php?rid=3260286&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1520984%3FCID%3Drss Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3260286 Tue, 09 Feb 2010 12:00:00 +0100 3260286 http://www.medworm.com/index.php?rid=3256012&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1521009%3FCID%3Drss The epigenetic control of gene expression has been shown to play an important role in cancer initiation, progression, and resistance. Thus, agents that modify the epigenetic environment of tumors will likely be an important addition to the anticancer arsenal. Specifically, there is much interest in modulating histone acetylation using a new class of drugs, histone deacetylase (HDAC) inhibitors. Preclinical data have demonstrated the efficacy of various HDAC inhibitors as anticancer agents, with the greatest effects shown when HDAC inhibitors are used in combination with other therapies. As a result of encouraging preclinical data, numerous HDAC inhibitors are being investigated in clinical trials either as monotherapies or in conjunction with other treatments such as chemotherapy, biologic... Cancer Network info http://www.medworm.com/rss/comments.php?id=3256012 Tue, 09 Feb 2010 12:00:00 +0100 3256012 http://www.medworm.com/index.php?rid=3256011&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1520918%3FCID%3Drss Cancer patients sometimes develop neurologic complications directly caused by their cancers. Sometimes, however, these disorders are due not to the growth of a cancer tumor but to cancer-fighting antibodies that mistakenly attack cells in the nervous system. PET/CT may help physicians tell the difference. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3256011 Tue, 09 Feb 2010 12:00:00 +0100 3256011 http://www.medworm.com/index.php?rid=3256010&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1521049%3FCID%3Drss Shabason et al have written a thoughtful review of an exciting new class of agents, histone deacetylase (HDAC) inhibitors. While the authors focus primarily on the role of HDAC inhibitors in combination with radiation therapy, we would like to highlight some potential strategies combining these agents with systemic therapies for the treatment of cancer. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3256010 Tue, 09 Feb 2010 12:00:00 +0100 3256010 http://www.medworm.com/index.php?rid=3256009&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1521067%3FCID%3Drss he treatment of B-cell malignancies has been revolutionized by the availability of safe and effective monoclonal antibodies. The addition of rituximab to standard chemotherapy regimens prolongs the survival of patients with diffuse large B-cell lymphoma (DLBCL) and follicular non-Hodgkin lymphoma. Nevertheless, indolent and mantle cell lymphomas remain incurable, and 30% to 40% of patients with DLBCL still die from their disease. Much ongoing research has focused on optimizing monoclonal antibody use, integrating them into multiagent regimens, and developing newer antibodies. Attempts to improve on the efficacy of monoclonal antibody–based therapy have included altering the dosing schedule, optimizing patient selection, maintenance therapy, improving upon the rituximab molecule, radioimm... Cancer Network info http://www.medworm.com/rss/comments.php?id=3256009 Tue, 09 Feb 2010 12:00:00 +0100 3256009 http://www.medworm.com/index.php?rid=3256008&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1520984%3FCID%3Drss Practitioners of Gerson therapy believe that cancer is caused by an accumulation of toxic substances in the body. They recommend a special diet including high carbohydrate and potassium intake, no sodium or fat, low animal protein, supplementation with exogenous digestive enzymes, and coffee enemas aimed at detoxifying the body and stimulating metabolism. However, available scientific evidence does not support use of Gerson therapy. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3256008 Tue, 09 Feb 2010 12:00:00 +0100 3256008 http://www.medworm.com/index.php?rid=3256007&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1520989%3FCID%3Drss The Takeda Oncology Company announced that the US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for bortezomib (Velcade), which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial (Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of bortezomib-based therapy in patients with previously untreated multiple myeloma (MM). (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3256007 Tue, 09 Feb 2010 12:00:00 +0100 3256007 http://www.medworm.com/index.php?rid=3256006&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1520996%3FCID%3Drss In the lead up to World Cancer Day on February 4, the theme of a campaign launched by the International Union Against Cancer (UICC) was “Cancer can be prevented too.” The campaign was backed by a new scientific report, “Protection Against Cancer-Causing Infections,” which focuses on the nine infections that can lead to cancer. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3256006 Tue, 09 Feb 2010 12:00:00 +0100 3256006 http://www.medworm.com/index.php?rid=3256005&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1521001%3FCID%3Drss Agendia, a leader in molecular cancer diagnostics, recently announced that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians. Over the past 3 years, the FDA has issued four clearances for MammaPrint, covering all aspects of this service. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3256005 Tue, 09 Feb 2010 12:00:00 +0100 3256005 http://www.medworm.com/index.php?rid=3209592&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1514773%3FCID%3Drss In this issue of ONCOLOGY, Comen and Robson provide a timely overview of poly(ADP-ribose) polymerase (PARP) inhibitors and their potential for the treatment of breast cancer. The authors highlight the recent demonstration of synthetic lethality between PARP inhibition and loss of either of the breast cancer susceptibility genes, BRCA1 and BRCA2, as well as the development of PARP inhibitors that are suitable for clinical therapy. However, many questions pertaining to both the basic biology of PARP inhibition and the potential clinical implications of PARP inhibitors still need to be addressed. In the following commentary, we highlight some of these remaining challenges. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3209592 Wed, 27 Jan 2010 13:30:01 +0100 3209592 http://www.medworm.com/index.php?rid=3205725&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1514162%3FCID%3Drss Some believed the unraveling of the human genome would lead overnight to the genetic tweaking of errant cells and the tailoring of treatments to patients. That dream’s time has not yet come, even a decade after the human genome was first sequenced. But the scientific community has made enormous progress in developing tools to examine the genome and their application. And those efforts may soon lead to practical results for mainstream oncology. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3205725 Tue, 26 Jan 2010 13:30:02 +0100 3205725 http://www.medworm.com/index.php?rid=3209600&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1514179%3FCID%3Drss Lung cancer remains the leading cause of cancer mortality, accounting for over 160,000 deaths in the United States and 1.18 million deaths worldwide each year.[1,2] Though tobacco smoking remains the most strongly associated risk factor for the development of lung cancer, 10% to 15% of lung cancer patients in the United States lack any history of tobacco use. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3209600 Tue, 26 Jan 2010 12:00:00 +0100 3209600 http://www.medworm.com/index.php?rid=3209599&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1514184%3FCID%3Drss Lung cancer is the leading cause of cancer death worldwide, responsible for over a million deaths annually. In the United States in 2009, it is estimated that 219,440 cases will be diagnosed and 159,390 deaths will be attributable to lung cancer.[1] The vast majority of these deaths are cigarette-smoking associated. However, an estimated 10% to 15% of these deaths will occur in “never-smokers.” (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3209599 Tue, 26 Jan 2010 12:00:00 +0100 3209599 http://www.medworm.com/index.php?rid=3209598&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1514321%3FCID%3Drss Peripheral T-cell lymphomas (PTCLs) are uncommonly encountered malignancies in the United States, and hepatosplenic T-cell lymphoma (HSTCL), subcutaneous panniculitis-like T-cell lymphoma (SPTCL), and enteropathy-type T-cell lymphoma (ETTCL) are rare subtypes of PTCLs that often present with primarily extranodal disease. Despite the fact that these tumors have distinct clinical and pathologic features, they are often diagnosed after significant delay. The combination of delay in diagnosis with ineffective therapies has resulted in a poor prognosis in most cases. Techniques that identify T-cell receptor gene rearrangements and flow cytometry that can identify characteristic immunophenotypes have guided our understanding of the underlying cell of origin of these rare PTCLs. As knowledge rega... Cancer Network info http://www.medworm.com/rss/comments.php?id=3209598 Tue, 26 Jan 2010 12:00:00 +0100 3209598 http://www.medworm.com/index.php?rid=3209597&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1514443%3FCID%3Drss The management of older patients with cancer is historically challenging because of a lack of prospective data regarding the appropriate management of this population. In this review, we address some of the issues and challenges surrounding the treatment of older cancer patients, including the withholding of medically appropriate treatment based on chronologic age, the historical omission of elderly from clinical trials, and the impact of geriatric assessment, and age-related changes in pharmacokinetics and pharmacodynamics. Finally, we conclude by discussing the existing evidence related to cancer treatment in the elderly, focusing primarily on the malignancies most commonly seen in older patients, and making general treatment recommendations where applicable. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3209597 Tue, 26 Jan 2010 12:00:00 +0100 3209597 http://www.medworm.com/index.php?rid=3209596&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1514486%3FCID%3Drss Drs. Gillison and Chatta present an up-to-date review of the systemic treatments available to elderly patients with the most common types of cancer. The only point I might add in the context of their review is about recently reported, promising data on targeted therapies in acute leukemia patients. A large proportion of older patients have acute lymphocytic leukemia positive for a t(9;22) translocation (Philadelphia chromosome–positive ALL). (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3209596 Tue, 26 Jan 2010 12:00:00 +0100 3209596 http://www.medworm.com/index.php?rid=3209595&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1514453%3FCID%3Drss Investigators from the Breast International Group 1-98 study and the Intergroup Exemestane Study updated their respective trial results at SABCS 2009. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3209595 Tue, 26 Jan 2010 12:00:00 +0100 3209595 http://www.medworm.com/index.php?rid=3209594&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1514491%3FCID%3Drss As knowledge increases about the processes underlying cancer, it is becoming feasible to design “targeted therapies” directed toward specific pathways that are critical to the genesis or maintenance of the malignant phenotype. Poly(ADP-ribose) polymerase (PARP) inhibitors are an example of this new framework. DNA damage repair is a complex and multifaceted process that is critical to cell survival. Members of the PARP family are central to specific DNA damage repair pathways, particularly the base excision repair (BER) pathway. PARP inhibition, with subsequent impairment of the BER mechanism, may enhance the cytotoxicity of agents that generate single-strand breaks in DNA, such as radiation and certain chemotherapy drugs. In addition, PARP inhibitors may induce death through “synthet... Cancer Network info http://www.medworm.com/rss/comments.php?id=3209594 Tue, 26 Jan 2010 12:00:00 +0100 3209594 http://www.medworm.com/index.php?rid=3209593&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1514718%3FCID%3Drss Pharmacologic strategies targeting the DNA of tumor cells have been in use for much of the past century for many different cancer types. Radiation has also been a long-employed strategy to cause DNA damage and subsequent tumor cell death. However, the class of agents designed to inhibit the enzyme poly-(ADP-ribose) polymerase (PARP) have taken this a step further—these agents do not damage DNA themselves, but rather, inhibit the repair of DNA via inhibition of the base excision single-strand repair pathway. PARP inhibitors have been shown preclinically and clinically to enhance the affects of chemotherapies known to damage DNA or interefere with DNA replication. However, the most exciting use of PARP inhibitors may be in exploiting the concept of synthetic lethality. In this setting, the... Cancer Network info http://www.medworm.com/rss/comments.php?id=3209593 Tue, 26 Jan 2010 12:00:00 +0100 3209593 http://www.medworm.com/index.php?rid=3199014&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1513259%3FCID%3Drss While they represent a minority of patients with lung cancer, more than 20,000 people in the United States who never smoked cigarettes are diagnosed with lung cancer each year.[1] This makes lung cancer in “never-smokers” one of the 10 most common cancers—more common than ovarian cancer. In this issue of ONCOLOGY, Subramanian and Govindan give an overview of emerging data about lung cancer in never-smokers.[2] The data outlined in this review provide support for the hypothesis that we can define this collection of diseases affecting never-smokers not by the absence of a common risk factor (smoking) but by each tumor’s molecular features. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3199014 Sat, 23 Jan 2010 13:30:01 +0100 3199014 http://www.medworm.com/index.php?rid=3199024&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1512661%3FCID%3Drss Multi-targeted TKI inhibitors are gaining traction in the treatment of advanced breast cancer, although results from four different trials do show varying degrees of efficacy. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3199024 Thu, 21 Jan 2010 12:00:00 +0100 3199024 http://www.medworm.com/index.php?rid=3199023&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1512694%3FCID%3Drss Sorafenib (Nexavar) has antiangiogenic and antiproliferative activity and is FDA-approved for advanced renal and hepatocellular cancers. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3199023 Thu, 21 Jan 2010 12:00:00 +0100 3199023 http://www.medworm.com/index.php?rid=3199022&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1512720%3FCID%3Drss There was good news at ASH 2009 on promising treatments for indolent lymphoma and aggressive non-Hodgkin's lymphoma. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3199022 Thu, 21 Jan 2010 12:00:00 +0100 3199022 http://www.medworm.com/index.php?rid=3199021&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1512725%3FCID%3Drss A 30-year study of nearly 20,000 Danish women made a defensible connection between obesity and poor prognosis after breast cancer diagnosis and treatment. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3199021 Thu, 21 Jan 2010 12:00:00 +0100 3199021 http://www.medworm.com/index.php?rid=3199020&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1512730%3FCID%3Drss The targeted combination of lapatinib (Tykerb) plus trastuzumab (Herceptin) led to a median overall survival of 14 months in women with refractory metastatic breast cancer. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3199020 Thu, 21 Jan 2010 12:00:00 +0100 3199020 http://www.medworm.com/index.php?rid=3199019&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1512770%3FCID%3Drss More is better, at least when it comes to treatments for multiple myeloma. Studies from Spanish and Italian investigators showed that upfront use of four drugs improves durable responses and progression-free survival in elderly patients. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3199019 Thu, 21 Jan 2010 12:00:00 +0100 3199019 http://www.medworm.com/index.php?rid=3199018&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1512784%3FCID%3Drss The Four Corners Breast Cancer Study is a population-based case-control study of women living in the southwestern states—Arizona, New Mexico, Colorado, and Utah. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3199018 Thu, 21 Jan 2010 12:00:00 +0100 3199018 http://www.medworm.com/index.php?rid=3199017&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1512789%3FCID%3Drss Fluorouracil, oxaliplatin (Eloxatin), and bevacizumab (Avastin) for first-line therapy is preferred in metastatic colon cancer. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3199017 Thu, 21 Jan 2010 12:00:00 +0100 3199017 http://www.medworm.com/index.php?rid=3199016&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1512807%3FCID%3Drss In order for a new treatment modality to be considered efficacious, it needs to be evaluated by acceptable criteria and demonstrate an improvement on the natural course of the disease. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3199016 Thu, 21 Jan 2010 12:00:00 +0100 3199016 http://www.medworm.com/index.php?rid=3199015&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1512812%3FCID%3Drss Patients with lower-risk myelodysplastic syndromes and anemia can derive long-term benefits from erythropoietin and myeloid growth factor hormones, according to a study in Blood. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3199015 Thu, 21 Jan 2010 12:00:00 +0100 3199015 http://www.medworm.com/index.php?rid=3186697&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1511962%3FCID%3Drss The standard for delivering the best quality of care to breast cancer patients calls for surgeons to consult with other specialists and to provide resources and education to help patients decide their course of treatment. That doesn't mean they do it. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3186697 Wed, 20 Jan 2010 13:30:02 +0100 3186697 http://www.medworm.com/index.php?rid=3199025&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1512421%3FCID%3Drss Prostate cancer patients administered high doses of proton-beam therapy appear to have a markedly reduced risk of disease recurrence when compared with other low-risk patients treated with conventional radiation therapy, according to two recent studies. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3199025 Wed, 20 Jan 2010 12:00:00 +0100 3199025 http://www.medworm.com/index.php?rid=3186698&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1511914%3FCID%3Drss fatty acids have gained popularity over the past decade as growing scientific evidence supports their use in preventing cardiovascular disease, depression, rheumatoid arthritis, and asthma, and in slowing cognitive decline. Because they are essential and cannot be synthesized in the human body, omega-3 fatty acids should be obtained through diet by consuming fish and nuts, or in supplemental form. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3186698 Tue, 19 Jan 2010 12:00:00 +0100 3186698 http://www.medworm.com/index.php?rid=3160717&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1509809%3FCID%3Drss As many as one in four cancer patients develop metastatic cancers of the brain. Existing therapies seldom do more than slow the disease. Adding to the urgency to find a way to prevent brain metastasis is the increasing number of such cases. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3160717 Tue, 12 Jan 2010 14:00:02 +0100 3160717 http://www.medworm.com/index.php?rid=3147024&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1507542%3FCID%3Drss Over 40 million men and women in the United States have osteoporosis and low bone mineral density (BMD), placing them at risk for adverse skeletal events such as fractures and their sequelae. There are over 12 million cancer survivors in this country. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3147024 Thu, 07 Jan 2010 13:30:02 +0100 3147024 http://www.medworm.com/index.php?rid=3143704&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1506976%3FCID%3Drss Adding cetuximab (Erbitux) to neoadjuvant chemotherapy shrank tumors enough to increase the success of curative surgery in colon cancer patients with inoperable metastatic liver lesions, according to the CELIM trial conducted in Germany and Austria. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3143704 Wed, 06 Jan 2010 13:30:01 +0100 3143704 http://www.medworm.com/index.php?rid=3154324&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1507486%3FCID%3Drss In addition to the direct effects of primary tumors in bone, bone complications in cancer patients occur from metastasis to bone and through the effects of cancer-related treatments and conditions. Bone is a very common metastatic site for many cancers, including myeloma, melanoma, and breast, prostate, thyroid, lung, bladder, and kidney cancers. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3154324 Wed, 06 Jan 2010 12:00:00 +0100 3154324 http://www.medworm.com/index.php?rid=3147028&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1507447%3FCID%3Drss More than 50% of patients with advanced breast or prostate cancer have identifiable bone metastasis, and 30% to 40% of patients with non–small-cell lung cancer ultimately develop metastases to bone.[1,2] Most tumors preferentially metastasize to the axial skeleton, targeting the vertebrae, pelvis, proximal ends of long bones, and skull.[3] (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3147028 Wed, 06 Jan 2010 12:00:00 +0100 3147028 http://www.medworm.com/index.php?rid=3147027&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1507472%3FCID%3Drss Despite the significant progress that has occurred in recent decades in the treatment of many advanced malignancies, skeletal morbidity remains a major problem for patients affected by cancers that metastasize to or grow primarily within bone.[1] (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3147027 Wed, 06 Jan 2010 12:00:00 +0100 3147027 http://www.medworm.com/index.php?rid=3147026&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1507486%3FCID%3Drss In addition to the direct effects of primary tumors in bone, bone complications in cancer patients occur from metastasis to bone and through the effects of cancer-related treatments and conditions. Bone is a very common metastatic site for many cancers, including myeloma, melanoma, and breast, prostate, thyroid, lung, bladder, and kidney cancers. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3147026 Wed, 06 Jan 2010 12:00:00 +0100 3147026 http://www.medworm.com/index.php?rid=3147025&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1507491%3FCID%3Drss Bone renewal is essential for bone strength. During childhood and early adulthood, bone formation prevails over bone resorption, as bones increase in size and strength. Peak bone mass is achieved during the third decade in life, with a higher peak bone mass being protective against osteoporosis later in life.[1] (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3147025 Wed, 06 Jan 2010 12:00:00 +0100 3147025 http://www.medworm.com/index.php?rid=3139876&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1506302%3FCID%3Drss PET scanning with FDG has proved its mettle as a way to judge tumor response to treatment. Now Australian researchers are going one step further and working with another radiotracer, which they have determined can monitor the response of non-small-cell lung cancer and normal tissue changes during radical chemoradiotherapy. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3139876 Tue, 05 Jan 2010 13:30:02 +0100 3139876 http://www.medworm.com/index.php?rid=3143709&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1506776%3FCID%3Drss A U.S. Preventive Services Task Force recommendation that routine breast cancer screening should begin at age 50, and take place every two years, did not sit well with the breast cancer community. The new recommendations will result in “many needless deaths,” stated the Society of Breast Imaging and the American College of Radiology. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3143709 Tue, 05 Jan 2010 12:00:00 +0100 3143709 http://www.medworm.com/index.php?rid=3143708&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1506824%3FCID%3Drss Precise and noninvasive, stereotactic radiosurgery is proving a godsend to some noncancer patients: Its use for applications outside oncology—such as the treatment of movement disorders, arteriovenous malformations, and neuralgia—have been around almost since the commercial introduction of this technology. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3143708 Tue, 05 Jan 2010 12:00:00 +0100 3143708 http://www.medworm.com/index.php?rid=3143707&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1506855%3FCID%3Drss The American College of Obstetricians and Gynecologists has recommended that women begin cervical cancer screening at age 21 rather than three years after the onset of sexual activity, as was previously recommended by the group. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3143707 Tue, 05 Jan 2010 12:00:00 +0100 3143707 http://www.medworm.com/index.php?rid=3143706&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1506881%3FCID%3Drss The Ivy Glioblastoma Atlas Project will track genetic mutations in glioblastoma multiforme and produce a free, online medical atlas. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3143706 Tue, 05 Jan 2010 12:00:00 +0100 3143706 http://www.medworm.com/index.php?rid=3143705&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1506951%3FCID%3Drss CHICAGO—FDG-PET imaging of non-small-cell lung cancer patients prior to receiving radiation therapy should not be the basis for determining areas that may benefit from higher doses of radiation, according to research out of Philadelphia’s Thomas Jefferson University Hospital. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3143705 Tue, 05 Jan 2010 12:00:00 +0100 3143705 http://www.medworm.com/index.php?rid=3127466&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1505082%3FCID%3Drss From naked antibodies to arsenic-laced molecules to anti-survivin antibodies, three up-and-coming agents are potential standouts in the lymphoma treatment arsenal. SGN-35 is an immunoconjugate that could offer a novel approach to Hodgkin’s lymphoma therapy. Then there are darinaparsin, an organic arsenic molecule, and YM155, which may be able to restore normal apoptotic activity in advanced and aggressive lymphoma, respectively. Researchers working with these drugs discuss their studies and trials while hematologic experts offer some perspective on the future of these agents. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3127466 Wed, 30 Dec 2009 13:30:01 +0100 3127466 http://www.medworm.com/index.php?rid=3125114&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1504943%3FCID%3Drss Micromet and Sanofi-aventis announced a global collaboration and license agreement to develop a BiTE antibody against a carcinoma cell antigen. Micromet will be responsible for the discovery, research, and development of the BiTE antibody through the completion of phase I clinical trials and under a joint steering committee’s supervision. Sanofi-aventis will have full responsibility for additional as well as worldwide commercialization of the BiTE antibody. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3125114 Tue, 29 Dec 2009 13:30:01 +0100 3125114 http://www.medworm.com/index.php?rid=3125120&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1504490%3FCID%3Drss Oncology specialists heaved a sigh of relief in November, after analysts from ASCO and ASTRO concluded that the worst had, in fact, not happened. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3125120 Mon, 28 Dec 2009 12:00:00 +0100 3125120 http://www.medworm.com/index.php?rid=3125119&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1504637%3FCID%3Drss Renal cell carcinoma represents 3% of all cancer cases but has a significant death rate associated with it: It’s estimated that there will be 60,000 new cases this year and 16,000 deaths from kidney cancer. The risk factors associated with kidney cancer include smoking, obesity, hypertension, and some occupational exposure. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3125119 Mon, 28 Dec 2009 12:00:00 +0100 3125119 http://www.medworm.com/index.php?rid=3125118&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1504652%3FCID%3Drss Shortages in funding, manpower, and willing patients have created the proverbial perfect storm in the current clinical trial system. The fact that traditional clinical trial endpoints in assessing novel agents are being reconsidered only puts more pressure on an already strained system. As the cancer research community navigates the troubled waters of clinical trials, one question is: Should traditional phase II trials be phased out? (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3125118 Mon, 28 Dec 2009 12:00:00 +0100 3125118 http://www.medworm.com/index.php?rid=3125117&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1504701%3FCID%3Drss Out with the old and in with the new is a commonly followed maxim in medicine given the rapid pace of developments in diagnosis and treatment. Human papillomavirus vaccines are relative newcomers to the cervical cancer armamentarium, but they cannot be relied on to do the job on their own; screening is still a must. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3125117 Mon, 28 Dec 2009 12:00:00 +0100 3125117 http://www.medworm.com/index.php?rid=3125116&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1504715%3FCID%3Drss Many women continue to experience pain and sensory disturbance up to three years after breast cancer treatment, according to Danish researchers, who found that younger women in particular reported persistent pain. They called for further strategies for improving pain management after breast surgery. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3125116 Mon, 28 Dec 2009 12:00:00 +0100 3125116 http://www.medworm.com/index.php?rid=3125115&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1504913%3FCID%3Drss NEW ORLEANS—Genentech and Biogen announced at ASH 2009 that the three-year follow-up of the CLL8 trial demonstrated that rituximab (Rituxan) plus fludarabine and cyclophosphamide (FC) chemotherapy improved overall survival in patients with previously untreated chronic lymphocytic leukemia (CLL) vs FC therapy alone. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3125115 Mon, 28 Dec 2009 12:00:00 +0100 3125115 http://www.medworm.com/index.php?rid=3090251&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1499146%3FCID%3Drss The targeted combination of lapatinib (Tykerb) plus trastuzumab (Herceptin) led to a median overall survival of 14 months in women with refractory metastatic breast cancer, according to an updated analysis of the phase III EGF104900 trial. A bonus: The majority of toxicities were low-grade. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3090251 Wed, 16 Dec 2009 13:30:01 +0100 3090251 http://www.medworm.com/index.php?rid=3085958&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1499062%3FCID%3Drss The RIBBON-2 trial met its primary endpoint to prolong progression-free survival, making the bevacizumab-chemotherapy combination a new treatment option, said principal investigator Adam Brufsky, MD. The trial continued the evaluation of bevacizumab plus chemotherapy to treat metastatic breast cancer after previous treatment failures. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3085958 Tue, 15 Dec 2009 13:30:01 +0100 3085958 http://www.medworm.com/index.php?rid=3090253&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1499129%3FCID%3Drss Researchers in Taiwan and China found that alternating mammography and ultrasound led to a higher cancer detection rate in women aged 40-49. Meanwhile in the UK, a group from West Midlands Research Collaborative have made a case for starting screening at age 40 in certain ethnic groups. Finally, German investigators assessed the value of semi-annual ultrasound exams in high-risk women. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3090253 Tue, 15 Dec 2009 12:00:00 +0100 3090253 http://www.medworm.com/index.php?rid=3090252&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1499138%3FCID%3Drss Despite a better dose loading schedule and compelling preclinical data, the combination of fulvestrant and anastrozole did not demonstrate any advantage in first relapse of hormone receptor-positive breast cancer, according to first results from the FACT trial. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3090252 Tue, 15 Dec 2009 12:00:00 +0100 3090252 http://www.medworm.com/index.php?rid=3080377&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1498123%3FCID%3Drss Denosumab prevented more events, was better tolerated, and was more convenient for breast cancer patients with skeletal metastasis, according to results from a randomized double-blind trial that matched the RANK ligand inhibitor against zoledronic acid. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3080377 Sat, 12 Dec 2009 13:30:02 +0100 3080377 http://www.medworm.com/index.php?rid=3076777&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1496598%3FCID%3Drss SAN ANTONIO—Options for breast cancer prevention range from “noninvasive” lifestyle changes (diet, nutrition, exercise) to more radical surgical approaches. During an SABCS 2009 educational session, Judy Garber, MD, from Boston’s Dana-Farber Cancer Institute, outlined some of the advances in chemoprevention of ER-negative/HER2-positive breast cancers. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3076777 Fri, 11 Dec 2009 13:30:01 +0100 3076777 http://www.medworm.com/index.php?rid=3080379&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1498107%3FCID%3Drss Results from the CONFIRM trial found that a higher dose of fulvestrant was significantly more effective than a lower dose but did not lead to more toxicity, reported Angelo DiLeo, MD, who added “we anticipate that the 500-mg regimen will become the established dose for fulvestrant.” (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3080379 Fri, 11 Dec 2009 12:00:00 +0100 3080379 http://www.medworm.com/index.php?rid=3080378&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1498113%3FCID%3Drss Exemestane alone and exemestane following tamoxifen, are equally appropriate treatment options, according to results from TEAM, the first trial prospectively powered to test the superiority of five years of aromatase inhibitors compared with a specific sequential strategy in postmenopausal women with endocrine-sensitive breast cancer. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3080378 Fri, 11 Dec 2009 12:00:00 +0100 3080378 http://www.medworm.com/index.php?rid=3076778&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1496593%3FCID%3Drss SAN ANTONIO—Investigators from Breast International Group 1-98 study and the Intergroup Exemestane Study updated their respective trial results at SABCS 2009. From the BIG 1-98 data, letrozole continued to show survival advantage, while exemestane offered protective benefits, based on IES study results. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3076778 Thu, 10 Dec 2009 12:00:00 +0100 3076778 http://www.medworm.com/index.php?rid=3068417&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1494540%3FCID%3Drss Ultrasound elastography may be the link bridging the gap between suspicion and definitive proof, a noninvasive means to distinguish between benign and malignant tissue. The technology for doing so appeared some years ago at the annual meeting of the Radiological Society of North America as an experimental curiosity. It’s been evolving since then until it appears now to have reached a clinical tipping point. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3068417 Wed, 09 Dec 2009 13:30:01 +0100 3068417 http://www.medworm.com/index.php?rid=3064198&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1493810%3FCID%3Drss SAN ANTONIO, TEX.—Clinical updates on the mother of all monoclonal antibodies and the link between bone and breast health will be ones-to-watch at SABCS 2009. Peter Ravdin, MD, PhD, shared his presentation picks at this year’s meeting with Oncology News International. Dr. Ravdin is on the SABCS executive committee and is based at the University of Texas Health Science Center in San Antonio. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3064198 Tue, 08 Dec 2009 13:30:01 +0100 3064198 http://www.medworm.com/index.php?rid=3064201&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1493758%3FCID%3Drss NEW ORLEANS—There was good news at ASH 2009 on promising treatments for indolent lymphoma and aggressive non-Hodgkin’s lymphoma. Also, a separate poster presentation showed that even just one cycle of post-remission therapy extended survival in elderly patients with acute myeloid leukemia. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3064201 Mon, 07 Dec 2009 12:00:00 +0100 3064201 http://www.medworm.com/index.php?rid=3064200&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1493770%3FCID%3Drss NEW ORLEANS—A new treatment for patients who are severely debilitated by myelofibrosis offers hope of a return to normal daily life. Preliminary studies with an oral drug INCB018424 that targets the Janus-activated kinase (JAK) 2 gene appears to markedly reduce the swelling of the spleen and sometimes the liver, which can, in turn, can change patients’ quality of life. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3064200 Mon, 07 Dec 2009 12:00:00 +0100 3064200 http://www.medworm.com/index.php?rid=3064199&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1493778%3FCID%3Drss NEW ORLEANS—More is better, at least when it comes to treatments for multiple myeloma. Separate studies from a Spanish group and an Italian group showed that up-front use of four drugs improves durable responses and progression-free survival in elderly patients. Both studies also showed that a kinder, gentler weekly schedule of bortezomib (Velcade) instead of the standard twice-weekly schedule maintains efficacy and reduces toxicity. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3064199 Mon, 07 Dec 2009 12:00:00 +0100 3064199 http://www.medworm.com/index.php?rid=3053774&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1492771%3FCID%3Drss NEW ORLEANS—The scientific program sessions are a unique offering at ASH, with an agenda that varies from the overall meeting. First, the speakers are invited to share their particular expertise with ASH attendees. Also, the abstracts are not peer-reviewed but are crafted specifically for the meeting. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3053774 Fri, 04 Dec 2009 13:30:01 +0100 3053774 http://www.medworm.com/index.php?rid=3049559&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1492337%3FCID%3Drss The oncology community is happy about next year’s cut in Medicare reimbursement. Well, maybe not so much happy as relieved. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3049559 Thu, 03 Dec 2009 13:30:01 +0100 3049559 http://www.medworm.com/index.php?rid=3045805&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1491054%3FCID%3Drss Oxygen therapies are expensive, unproven, and harmful alternatives promoted in appealing and convincing ways for the treatment of cancer and other major diseases. Supporters claim that low levels of oxygen enable cancer cells to thrive and that an oxygen-rich environment destroys them. However, these claims are unsubstantiated. Further, numerous reports of serious complications and fatalities have been reported from the use of oxygen therapies. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3045805 Wed, 02 Dec 2009 13:30:01 +0100 3045805 http://www.medworm.com/index.php?rid=3027620&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1489801%3FCID%3Drss More than 60 years ago, Karnofsky and colleagues reported promising results with the introduction of nitrogen mustard, the prototype of alkylating agents, for the treatment of lung cancer.[1] (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3027620 Thu, 26 Nov 2009 13:30:01 +0100 3027620 http://www.medworm.com/index.php?rid=3027622&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1489775%3FCID%3Drss Since the publication of a meta-analysis in 1995 that demonstrated a modest survival benefit compared to best supportive care, platinum-based chemotherapy became the cornerstone of therapy in the first-line setting in advanced-stage non–small-cell lung cancer (NSCLC) for patients with good performance status.[1] (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3027622 Wed, 25 Nov 2009 12:00:00 +0100 3027622 http://www.medworm.com/index.php?rid=3027621&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1489796%3FCID%3Drss Recent studies have shed new light on the role of histology in predicting sensitivity to therapeutic agents such as pemetrexed (Alimta) or bevacizumab (Avastin). Whereas during the past 30 years, the only useful histologic consideration was the absence or presence of a “non” before “small-cell lung cancer,” (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3027621 Wed, 25 Nov 2009 12:00:00 +0100 3027621 http://www.medworm.com/index.php?rid=3019984&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1489613%3FCID%3Drss Surgical intervention for mesothelioma has become widely accepted, but controversy persists: Should surgery be the standard of care or should it be offered only to select patients? According to scientific literature, surgery decreases morbidity and mortality while also improving outcomes compared with adjunctive therapy alone. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3019984 Tue, 24 Nov 2009 13:30:02 +0100 3019984 http://www.medworm.com/index.php?rid=3019988&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1489656%3FCID%3Drss Precise and noninvasive, stereotactic radiosurgery is proving a godsend to some noncancer patients. Its use for applications outside oncology, such as the treatment of movement disorders, arteriovenous malformations, and neuralgia, have been around almost since the commercial introduction of this technology. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3019988 Mon, 23 Nov 2009 12:00:00 +0100 3019988 http://www.medworm.com/index.php?rid=3019987&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1489434%3FCID%3Drss Radiofrequency ablation can decrease disease progression in patients with dysplastic Barrett esophagus, or metaplasia of the espophageal epithelium, according to a study out of the University of North Carolina in Chapel Hill. The researchers also found that the technique eradicated dysplasia and intestinal metaplasia. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3019987 Mon, 23 Nov 2009 12:00:00 +0100 3019987 http://www.medworm.com/index.php?rid=3019986&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1489439%3FCID%3Drss The first major study to address the cardiovascular adverse effects of endocrine therapy for prostate cancer could change attitudes toward treatment options because testosterone deprivation may have more impact on the patient’s life than it does on the androgen receptor. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3019986 Mon, 23 Nov 2009 12:00:00 +0100 3019986 http://www.medworm.com/index.php?rid=3019985&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1489452%3FCID%3Drss MINNEAPOLIS—When it comes to taking stock of an oncology practice’s productivity, less is more. It benefits a practice to develop a few meaningful benchmarks rather than multiple overlapping, overwhelming, and meaningless measurements. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3019985 Mon, 23 Nov 2009 12:00:00 +0100 3019985 http://www.medworm.com/index.php?rid=3013623&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1489101%3FCID%3Drss Researchers are exploring ways to manipulate rituximab (Rituxan) when added to the current standard therapy for diffuse large B-cell lymphoma, specifically shortening the number of treatment days. Preliminary results of a phase III trial showed that rituximab plus CHOP over a 14-day cycle achieved similar response rates and comparable toxicity compared to CHOP on a 21-day cycle in newly diagnosed patients. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3013623 Sat, 21 Nov 2009 13:30:02 +0100 3013623 http://www.medworm.com/index.php?rid=3009635&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1488736%3FCID%3Drss A review article asserting breast MRI does not improve surgical planning, reduce follow-up surgeries, or reduce the risk of local recurrences drew the ire of the breast imaging community. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3009635 Fri, 20 Nov 2009 13:30:01 +0100 3009635 http://www.medworm.com/index.php?rid=3013625&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1488980%3FCID%3Drss In a prepared statement, Dr. Brawley said the ACS stands by its recommendation that women 40 years and older should receive annual mammography screening, and women at high risk should talk with their doctors about when screening should begin based on their family history. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3013625 Fri, 20 Nov 2009 12:00:00 +0100 3013625 http://www.medworm.com/index.php?rid=3013624&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1489041%3FCID%3Drss Ultrasound is an effective way to monitor lymph node recurrence after breast cancer surgery, South Korean researchers reported. Regional lymph node recurrence affects just 2% to 16% of patients with any stage of breast cancer, but is difficult to manage and associated with poor prognosis. (Source: Cancer Network) Cancer Network info http://www.medworm.com/rss/comments.php?id=3013624 Fri, 20 Nov 2009 12:00:00 +0100 3013624